News

Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology Demonstrating Therapeutic Antibody Transcytosis Across the Kidney Barrier After Intravenous Administration

Schlieren / Zurich, Switzerland, 11 June, 2025 – Memo Therapeutics AG (or “MTx”), a late-stage biotechnology company developing antibody-based therapies for viral infections and cancer, has published a study in Frontiers in Pharmacology detailing the transport of therapeutic IgG1 antibodies across the kidney endothelial barrier. This quantitative analysis provides a scientific basis for the...

read more

InSphero and Hesperos Announce Strategic Collaboration to Offer End-to-End Solutions in Drug Discovery and Toxicology

InSphero, the global leader in industry-ready 3D in vitro solutions for preclinical research, announced a new collaborative partnership with Hesperos, uniting two leading innovators in the field of advanced in vitro and microphysiological (MPS) systems. This partnership will provide pharmaceutical and biotechnology companies with bespoke, integrated solutions spanning the entire drug development pipeline from early-stage screening...

read more

InSphero Expands 3D Microtissue Portfolio Through Strategic Agreement with Tessara Therapeutics

InSphero, the global leader in scalable and reliable 3D in vitro cell culture solutions for drug discovery, has entered into a distribution agreement with Tessara Therapeutics, an Australian biotech company known for its advanced neuronal microtissue technology. This agreement further strengthens our portfolio of physiologically relevant 3D models and enables us to offer best-in-class neuronal...

read more